Charles Ferté

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou et al. · The Lancet Oncology · 2018 · 1.2K citations

Medicine, Immunology, Oncology +17

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari et al. · Clinical Cancer Research · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +17

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté et al. · Cancer Discovery · 2017 · 776 citations

Medicine, Molecular Biology, Oncology +17

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 738 citations · Full text

Medicine, Oncology, Pharmacology +14

Exomics and immunogenics

Stéphane Champiat, Charles Ferté, Sophie Lebel‐Binay et al. · OncoImmunology · 2014 · 190 citations · Full text

Medicine, Immunology, Oncology +17